Show simple item record

dc.contributor.authorLashford, Linda S
dc.date.accessioned2010-03-24T10:14:58Z
dc.date.available2010-03-24T10:14:58Z
dc.date.issued1997-02
dc.identifier.citationPossibilities of gene therapies for cancer. 1997, 29 (1):1-4 Ann. Med.en
dc.identifier.issn0785-3890
dc.identifier.pmid9073318
dc.identifier.urihttp://hdl.handle.net/10541/94796
dc.description.abstractCancer is an acquired disease in which it is possible to identify a variety of abnormalities at a genetic level. This holds a promise that genetic manipulation of tumour cells will lead to novel therapies. As yet these approaches are constrained by available methods for obtaining gene transfer and subsequent genetic control. However, a number of strategies are already reaching the clinic, including attempts at immunotherapy, prodrug activation and improving host defence against conventional chemotherapy. Further clinical opportunities will occur with improved vector development.
dc.language.isoenen
dc.subjectCanceren
dc.subjectExperimental Canceren
dc.subject.meshAnimals
dc.subject.meshGene Therapy
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.subject.meshNeoplasms, Experimental
dc.titlePossibilities of gene therapies for cancer.en
dc.typeArticleen
dc.identifier.journalAnnals of Medicineen
html.description.abstractCancer is an acquired disease in which it is possible to identify a variety of abnormalities at a genetic level. This holds a promise that genetic manipulation of tumour cells will lead to novel therapies. As yet these approaches are constrained by available methods for obtaining gene transfer and subsequent genetic control. However, a number of strategies are already reaching the clinic, including attempts at immunotherapy, prodrug activation and improving host defence against conventional chemotherapy. Further clinical opportunities will occur with improved vector development.


This item appears in the following Collection(s)

Show simple item record